参考文献/References:
[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6): 394-424.[2]Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.[3]Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group[J].World Health Organ Tech Rep Ser,1994(843):1-129.[4]Kanis JA,Johnell O,Oden A,et al.Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds[J].Osteoporos Int,2001,12(12):989-995.[5]Shapiro CL,Van Poznak C,Lacchetti C,et al.Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline[J].J Clin Oncol,2019, 37(31):2916-2946.[6]Si L,Winzenberg TM,Jiang Q,et al.Projection of osteoporosis-related fractures and costs in China:2010-2050[J].Osteoporos Int,2015,26(7):1929-1937.[7]D’oronzo S,Coleman R,Brown J,et al.Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management[J].J Bone Oncol,2019(15):004-4.[8]孔令泉,吴凯南,果磊.乳腺癌伴随疾病学[M].北京:科学出版社,2019:74-94.[9]Nicolin V,Bortul R,Bareggi R,et al.Breast adenocarcinoma MCF-7 cell line induces spontaneous osteoclastogenesis via a RANK-ligand-dependent pathway[J].Acta Histochem,2008,110(5):388-396.[10]Kyvernitakis I,Kostev K,Hadji P.The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer[J].Osteoporos Int,2018,29(11):2557-2564.[11]Kalder M,Hans D,Kyvernitakis I,et al.Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer[J].J Clin Densitom,2014,17(1):66-71.[12]Ramchand SK,Cheung YM,Grossmann M.Bone health in women with breast cancer[J].Climacteric,2019:1-7.[13]Ruhstaller T,Giobbie-Hurder A,Colleoni M,et al.Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial[J].J Clin Oncol,2019,37(2):105-114.[14]Hong AR,Kim JH,Lee KH,et al.Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer[J].Osteoporos Int,2017,28(4):1413-1422.[15]Tseng OL,Spinelli JJ,Gotay CC,et al.Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis[J].Ther Adv Musculoskelet Dis,2018, 10(4):71-90.[16]Axelsen CT,Jensen AB,Jakobsen EH,et al.Bone loss during neoadjuvant/adjuvant chemotherapy for early stage breast cancer: A retrospective cohort study[J].Mol Clin Oncol,2018,8(6):767-772.[17]Taxel P,Faircloth E,Idrees S,et al.Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer[J].J Endocr Soc,2018,2(7):574-588.[18]Bouvard B,Confavreux CB,Briot K,et al.French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies[J].Joint Bone Spine,2019,86(5):542-553.[19]Hadji P,Aapro MS,Body JJ,et al.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG[J].J Bone Oncol,2017(7):1-12.[20]中国乳腺癌内分泌治疗多学科管理骨安全共识专家组.绝经后早期乳腺癌芳香化酶抑制剂治疗相关的骨安全管理中国专家共识[J]中华肿瘤杂志,2015(7):554-558.[21]戴威,孔令泉,吴凯南.乳腺癌伴随疾病全方位管理之骨健康管理[J].中国临床新医学,2019(2):145-149.[22]Hillner BE,Ingle JN,Chlebowski RT,et al.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer[J].J Clin Oncol, 2003,21(21):4042-4057.[23]Henry D,Vadhan-Raj S,Hirsh V,et al.Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors[J].Support Care Cancer,2014,22(3):679-687.
相似文献/References:
[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像
在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,31(07):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Medical Information,2022,35(07):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,31(07):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘雪静,路 红,徐熠琳,等.乳腺影像与容积导航技术初步应用的临床分析[J].医学信息,2022,35(11):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
LIU Xue-jing,LU Hong,XU Yi-lin,et al.Clinical Analysis of the Preliminary Application of Breast Imaging and Volume Navigation Technology[J].Medical Information,2022,35(07):161.[doi:10.3969/j.issn.1006-1959.2022.11.043]
[6]刘在波,修文娟.背阔肌皮瓣联合假体在乳腺癌改良根治术后乳房重建中的应用[J].医学信息,2019,32(02):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
LIU Zai-bo,XIU Wen-juan.Application of Latissimus Dorsi Flap Combined with Prosthesis in Breast Reconstruction after Modified Radical Mastectomy for Breast Cancer[J].Medical Information,2019,32(07):127.[doi:10.3969/j.issn.1006-1959.2019.02.036]
[7]孟庆国,王佳雪,王斯佳.马来酸吡咯替尼对乳腺癌术后患者心脏功能的影响[J].医学信息,2019,32(02):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
MENG Qing-guo,WANG Jia-xue,WANG Si-jia.Effect of Pyrrolidine Maleate on Cardiac Function in Patients after Breast Cancer Operation[J].Medical Information,2019,32(07):152.[doi:10.3969/j.issn.1006-1959.2019.02.045]
[8]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与
健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,31(07):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[9]满枋霖,葛俊宏,林晓月,等.p21活化激酶在乳腺癌中的作用研究[J].医学信息,2019,32(06):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
MAN Fang-lin,GE Jun-hong,LIN Xiao-yue,et al.The Role of p21 Activated Kinase in Breast Cancer[J].Medical Information,2019,32(07):35.[doi:10.3969/j.issn.1006-1959.2019.06.013]
[10]张天竺,宁 勇.长链非编码RNA调控乳腺癌发生发展的研究进展[J].医学信息,2019,32(12):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]
ZHANG Tian-zhu,NING Yong.Advances in Research on Long-chain Non-coding RNA Regulation of Breast Cancer Development[J].Medical Information,2019,32(07):40.[doi:10.3969/j.issn.1006-1959.2019.12.014]